Your source for all Prime Therapeutics' April 2025 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for April 2025 will keep you informed on what’s trending now.

Released April 15, 2025

High-Cost Therapy Profile

roviding a clinical deep dive into a select high cost drug in the pipeline, this month’s profile features Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic and more.

Released April 14, 2025

FDA Decisions Expected for May 2025

A breakdown of FDA decisions expected of new drugs expected to hit the market, this edition covers ustekinumab biosimilar (BAT2206), pegzilarginase and more.

Oncology Insights

Featuring commentary by Simone Ndujiuba, PharmD, BCOP on developments in the oncology space, this installment features approved innovative therapy and the continued unmet needs of pancreatic cancer.

Released April 2, 2025

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel / (Abeona), brensocatib / Insmed, rebisufligene etisparvovec / (Ultragenyx) and more.

Looking for previous 2025 drug insights publications?

Simply click on the month to access past editions of our drug insights.

March 2025

February 2025

January 2025

All brand names are property of their respective owners.